FY2028 EPS Estimates for Denali Therapeutics Inc. (NASDAQ:DNLI) Lowered by Analyst

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities research analysts at Wedbush cut their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. Wedbush analyst L. Chico now forecasts that the company will earn $1.74 per share for the year, down from their prior estimate of $1.83. Wedbush currently has a “Outperform” rating and a $30.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.61) per share.

A number of other equities research analysts have also recently commented on DNLI. The Goldman Sachs Group cut their target price on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Denali Therapeutics in a research note on Wednesday. Stifel Nicolaus decreased their price objective on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday. Finally, UBS Group decreased their target price on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.22.

Denali Therapeutics Trading Down 0.9 %

DNLI traded down $0.16 during trading on Friday, reaching $18.51. The stock had a trading volume of 88,360 shares, compared to its average volume of 1,165,433. The stock’s 50 day moving average is $18.77 and its two-hundred day moving average is $18.84. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of -17.29 and a beta of 1.39. Denali Therapeutics has a one year low of $14.56 and a one year high of $33.31.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same period in the prior year, the business earned ($0.80) earnings per share.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds have recently modified their holdings of DNLI. Norges Bank purchased a new position in shares of Denali Therapeutics during the fourth quarter worth approximately $24,736,000. Braidwell LP purchased a new position in Denali Therapeutics in the 4th quarter valued at $9,910,000. Principal Financial Group Inc. grew its position in Denali Therapeutics by 57.9% in the 4th quarter. Principal Financial Group Inc. now owns 1,073,704 shares of the company’s stock valued at $23,042,000 after buying an additional 393,626 shares during the last quarter. Vanguard Group Inc. grew its position in Denali Therapeutics by 3.5% in the 3rd quarter. Vanguard Group Inc. now owns 10,597,781 shares of the company’s stock valued at $218,632,000 after buying an additional 354,798 shares during the last quarter. Finally, abrdn plc purchased a new position in Denali Therapeutics in the 4th quarter valued at $6,971,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Denali Therapeutics news, Director Steve E. Krognes sold 2,750 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total transaction of $47,547.50. Following the completion of the transaction, the director now owns 139,841 shares of the company’s stock, valued at $2,417,850.89. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Steve E. Krognes sold 2,750 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $47,547.50. Following the sale, the director now owns 139,841 shares of the company’s stock, valued at $2,417,850.89. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the completion of the sale, the director now directly owns 118,043 shares in the company, valued at approximately $2,159,006.47. The disclosure for this sale can be found here. Insiders sold 110,955 shares of company stock worth $2,218,802 over the last three months. Insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.